CD4 and cancer: Chimeric antigen receptor (CAR) T cell therapy for HIV actually predates its use in cancer, with the first studies completed in the mid 1990's, when a CD4-based CAR, shown to be effective in vitro and safe and well-tolerated in vivo, provided no clear clinical benefit and no reduction in the peripheral viral reservoir (159, 160).